Nanobiotix Presents Promising Early Phase 2 Trial Data for JNJ-1900 in Lung Cancer

Nanobiotix, a biotech company, has disclosed promising early results from Part 1 of a Phase 2 clinical trial involving JNJ-1900 (NBTXR3) for stage 3 inoperable non-small cell lung cancer. The data was unveiled at the European Society for Radiotherapy and Oncology meeting of 2026.

The trial, sponsored by Johnson & Johnson, evaluates the intratumoral injection of JNJ-1900 combined with chemoradiotherapy and consolidation with durvalumab. Initial findings show an overall response rate of 85.7% among the seven participants, with a complete response in 57.1% of cases. Importantly, there was a disease control rate of 100%, with no signs of disease progression observed.

The positive early efficacy results indicate potential long-term benefits, though further trials are necessary to confirm these findings.